Phase II Data With Dusa's Levulan

10 March 1997

- Data from Phase II clinical trials with Dusa Pharmaceuticals'Levulan (amino-laevulinic acid), a photodynamic therapy for precancerous actinic keratoses of the skin, have shown a complete clearance of lesions after one to two treatments. Phase III studies have begun, and are expected to conclude this year; Dusa plans to file a New Drug Application with the US authorities shortly after. Phase I/II trials in bladder cancer and hair removal, as well as further studies in acne and endometrial ablation, are also planned this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight